Treatment of Lennox-Gastaut syndrome evolved from another epilepsy syndrome, when the patient is not already on sodium valproate
This protocol covers a specific patient group: individuals with Lennox-Gastaut syndrome (LGS) whose condition has evolved from a prior epilepsy syndrome — such as infantile epileptic spasms syndrome (IESS) — and who are not currently receiving sodium valproate as part of their treatment.
Clinical scenario
Many patients receive anti-seizure medication (ASM) therapy to control seizures before LGS is formally diagnosed, or develop LGS after progressing over time from a prior epilepsy syndrome. Patients who are not already being treated with valproate in this context should be transitioned to valproate and then managed using a structured LGS treatment algorithm.
Treatment approach — partial overview
The approach centres on establishing sodium valproate within the regimen. Where seizure control remains inadequate after valproate is introduced, further adjustment of the anti-seizure medication combination may be warranted — potentially incorporating lamotrigine while tapering off the prior non-valproate agent.
Complete sequencing, decision criteria, and full regimen details are available in the structured protocol below.
References
DOI: 10.1002/epi4.13075
- Patients with LGS that has evolved from another type of epilepsy who are not already being treated with valproate should be transitioned to valproate and then managed using the same algorithm as for newly diagnosed LGS.
- Many patients will either have been treated with ASM therapy to initially control seizures before LGS diagnosis or will have developed LGS having progressed over time from another epilepsy syndrome, such as IESS.
- If seizure control is inadequate after introducing VPA and the second ASM is not LTG, then LTG should be initiated and the other non-VPA ASM tapered off and discontinued.
View source ↗